Advertisement

Editorial to "Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study" by Friedman et al.

      When things go wrong in chronic diseases, there are always two sets of problems. One is how to fix what's wrong. The second is what this problem portends. Parkinson's disease (PD) offers a number of ways in which things can go wrong, both from disease progression, as well as from iatrogenic complications, which usually, indirectly, reflect disease progression. Psychotic symptoms in PD are, unfortunately common, affecting about 20–30% of treated patients [
      • Forsaa E.
      • Larsen J.
      • Wentzel-Larsen T.
      • Goetz C.G.
      • Stebbins G.T.
      • Aarsland D.
      • Alves G.
      A 12 year population-based study of psychosis in Parkinson's disease.
      ] and increasingly prevalent as the disease advances, with up to 60% [
      • Diederich N.J.
      • Fenelon G.
      • Stebbins G.
      • Goetz C.G.
      Hallucinations in Parkinson's disease.
      ] developing symptoms by the time of death.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Parkinsonism & Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Forsaa E.
        • Larsen J.
        • Wentzel-Larsen T.
        • Goetz C.G.
        • Stebbins G.T.
        • Aarsland D.
        • Alves G.
        A 12 year population-based study of psychosis in Parkinson's disease.
        Arch. Neurol. 2010; 67: 996-1001
        • Diederich N.J.
        • Fenelon G.
        • Stebbins G.
        • Goetz C.G.
        Hallucinations in Parkinson's disease.
        Nat. Rev. Neurol. 2009; 5: 331-342
        • Rodriguez-Violante M.
        • Camacho-Ordonez A.
        • Cervantes-Arriaga A.
        • Gonzalez-Latapi P.
        • Velazquez-Osuna S.
        Factors associated with the quality of life of subjects with Parkinsons' disease and burden on their caregivers.
        Neurologica. 2015; 30: 257-263
        • Klein C.
        • Prokhorov V.
        • Miniovitz A.
        • Dobronevsky E.
        • Rabey J.M.
        Admission of Parkinsonian patients to a neurological ward in a community hospital.
        J. Neural Transm. 2009; 116: 1509-1512
        • Aarsland D.
        • Larsen J.
        • Tandberg E.
        • Laake K.
        Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.
        J. Am. Geriatr. Soc. 2000; 48: 938-942
        • Goetz C.G.
        • Fan W.
        • Leurgans S.
        • Bernard B.
        • Stebbins G.T.
        The malignant course of “benign hallucinations” in Parkinson's disease.
        Arch. Neurol. 2006; 63: 713-716
        • Parkinson Study Group
        Low dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease.
        N. Engl. J. Med. 1999; 340: 757-763
        • Forsaa E.
        • Larsen J.
        • Wentzel-Larsen T.
        • Alves G.
        What predicts mortality in Parkinson's disease? A prospective population-based long-term study.
        Neurology. 2010; 75: 1270-1276
      1. Wetmore JB, Li S, Yan H, Irfan M, Rashid N, Peng Y, Gilbertson DT, Shim A. Increases in Institutionalization, Healthcare Resource Utilization, and Mortality Risk Associated Wtih Parkinson Disease Psychosis: Retrospective Cohort Study. PRD-D-19-00787R1.

        • Compta Y.
        • Pereira J.B.
        • Rios J.
        • Ibarretxe-Bilbao N.
        • Junque C.
        • Bargalio N.
        • Camara A.
        • Buongiorno M.
        • Fernandez M.
        • Pont-Sunyer C.
        • Marti M.J.
        Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study.
        Park. Relat. Disord. 2013; 19: 1071-1072
        • Han W.
        • Sapkota S.
        • Camicioli R.
        • Dixon R.A.
        • Li L.
        Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomics analysis.
        Mov. Disord. 2017; 32: 1720-1728
        • Smith C.
        • Malek N.
        • grosset K.
        • Cullen B.
        • Gentleman S.
        • Grosset G.
        Neuropathology of dementia in patients ith Parkinson's disease: a systematic review of autopsy studies.
        J. Neurol. Neurosurg. Psychiatry. 2019; 90: 1234-1243
        • Espay A.J.
        • Guskey M.T.
        • Norton J.C.
        • Coate B.
        • Vizcarra J.A.
        • Ballard C.
        • et al.
        Pimavanserin for Parkinson disease psychosis: effects stratified by baseline cognition and use of cognitive enhancing medications.
        Mov. Disord. 2018; 33: 769-776